GETTING YOUR PATIENTS STARTED ON XCOPRI® (CENOBAMATE TABLETS) CV

XCOPRI IS WIDELY ACCESSIBLE FOR YOUR PATIENTS

3 OUT OF 4 PATIENTS HAVE ACCESS TO XCOPRI AS INITIAL THERAPY*

These patients do not need to try and fail other anti-seizure medications, including generics, for XCOPRI to be covered by their insurance.



PATIENTS CAN RECEIVE THEIR FIRST MONTH PRESCRIPTION FOR $0 THROUGH THE TRIAL OFFER OR STARTER SAMPLE PROGRAM†

Starter samples are ordered and distributed by the doctor's office. You can request samples from your sales representative or through **XCOPRIhcp.com**.

Scan here with your mobile device to download the free Trial Offer

XCOPRI COVERAGE

Nationally, **9 out of 10** Commercial, Medicare, and Medicaid patients have coverage for XCOPRI.*
If a prior authorization is required, ~90% of PAs are approved based solely on indication.*

PATIENT CATEGORY	XCOPRI OUT-OF-POCKET COST
Commercial	Eligible patients may pay as little as $20 per month. Copay assistance is automatically applied at the retail pharmacy.†
Medicare Extra Help (i.e., Medi-medi, dual-eligible, LIS)	Less than $15 copay. 85% of XCOPRI Medicare patients receive Medicare Extra Help.‡
Medicaid only	Less than $5 per prescription
Medicare only	Plans vary. Your patient will need to consult with their plan for out-of-pocket costs.

*Managed Markets Insight & Technology, LLC, database as of December 2024.
†Eligibility requirements and terms and conditions will apply.
‡IQVIA DE/LI Oct 2023 - Sept 2024.

SETTING EXPECTATIONS FOR YOUR PATIENT AT THE PHARMACY

Availability
Any pharmacy can fill an XCOPRI prescription. Pharmacies will need to order XCOPRI once they receive a prescription, and it should arrive in 1-3 business days.

Refills
Ask your patients to call the pharmacy one week before their next prescription to ensure it is ordered and stocked.

If your patient is having any issues filling XCOPRI at the pharmacy, have them call our support program at 1-833-PHARM-SK (742-7675).

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

INDICATION
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

CONTRAINDICATIONS
XCOPRI is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

Please see additional Important Safety Information and full Prescribing Information.

XCOPRI®
(cenobamate tablets) C
12.5 • 25 • 50 • 100 • 150 • 200 mg

WE ARE HERE TO HELP MAXIMIZE ACCESS FOR YOUR PATIENT

GET SUPPORT WITH SK LIFE SCIENCE NAVIGATOR

Regardless of your patient's insurance, our dedicated team can provide the following:

Scan code to visit sklsinavigator.com or call (866) 756-2844

SUPPORT FOR YOUR PATIENTS

- Can provide free products to eligible patients who are uninsured, underinsured, or experiencing financial hardships
- Help to locate XCOPRI if your patient's local pharmacy does not have it in stock

SUPPORT FOR YOU

- Help identify whether a patient's insurance plan covers XCOPRI
- If a PA is required, we'll help provide the information that is needed
- Downloadable sample letter of appeal, medical necessity, and more

GET SUPPORT THROUGH SPECIALTY PHARMACY

Need quick access to XCOPRI or prior authorization support? We've got you covered.

Resolving Prior Authorization requests

Refill reminders

Convenient home delivery for your patients. Urgent requests can be delivered overnight

LEARN MORE ABOUT SPECIALTY PHARMACY SUPPORT

Scan the QR code or click here for additional information about our specialty pharmacy partners

SK life science
a subsidiary of SK biopharmaceuticals

PM-US-XCOP-1339

XCOPRI®
(cenobamate tablets) Ⓒ
12.5 • 25 • 50 • 100 • 150 • 200 mg

XCOPRI® (cenobamate tablets) CV is indicated for the treatment of partial-onset seizures in adult patients[1]

XCOPRI PRESCRIBING GUIDE

XCOPRI® (cenobamate tablets) CV
12.5 • 25 • 50 • 100 • 150 • 200 mg

ONCE-DAILY XCOPRI IS TITRATED AT 2-WEEK INTERVALS AND CAN BE PRESCRIBED AS MONOTHERAPY AND ADJUNCTIVE THERAPY.

12.5 mg / 25 mg
(NDC 71699-0201-28)

XCOPRI Titration Pack

- **Directions for Use:** Take 12.5 mg tablet by mouth once daily for 2 weeks; take 25 mg tablet by mouth once daily for 2 weeks
- **Quantity:** 28 • **Refills:** 0

50 mg / 100 mg
(NDC 71699-0202-28)

XCOPRI Titration Pack

- **Directions for Use:** Take 50 mg tablet by mouth once daily for 2 weeks; take 100 mg tablet by mouth once daily for 2 weeks
- **Quantity:** 28 • **Refills:** 0

150 mg / 200 mg
(NDC 71699-0203-28)

XCOPRI Titration Pack

- **Directions for Use:** Take 150 mg tablet by mouth once daily for 2 weeks; take 200 mg tablet by mouth once daily for 2 weeks
- **Quantity:** 28 • **Refills:** 0

25 mg
(NDC 71699-0025-30)

XCOPRI Bottle

- **Directions for Use:** Take 25 mg tablet by mouth once daily
- **Quantity:** 30 • **Refills:** (per HCP discretion)

50 mg
(NDC 71699-0050-30)

XCOPRI Bottle

- **Directions for Use:** Take 50 mg tablet by mouth once daily
- **Quantity:** 30 • **Refills:** (per HCP discretion)

100 mg
(NDC 71699-0100-30)

XCOPRI Bottle

- **Directions for Use:** Take 100 mg tablet by mouth once daily
- **Quantity:** 30 • **Refills:** (per HCP discretion)

150 mg
(NDC 71699-0150-30)

XCOPRI Bottle

- **Directions for Use:** Take 150 mg tablet by mouth once daily
- **Quantity:** 30 • **Refills:** (per HCP discretion)

200 mg
(NDC 71699-0200-30)

XCOPRI Bottle

- **Directions for Use:** Take 200 mg tablet by mouth once daily
- **Quantity:** 30 • **Refills:** (per HCP discretion)

300 mg
(NDC 71699-0150-30)

XCOPRI Bottles

- **Directions for Use:** If prescribed 300 mg/day, write a prescription for two of the 150 mg bottles. Take two 150 mg tablets by mouth once daily
- **Quantity:** 60 • **Refills:** (per HCP discretion)

400 mg
(NDC 71699-0200-30)

XCOPRI Bottles

- **Directions for Use:** If prescribed 400 mg/day, write a prescription for two of the 200 mg bottles. Take two 200 mg tablets by mouth once daily
- **Quantity:** 60 • **Refills:** (per HCP discretion)

250 mg
(150 mg and 100 mg)
(NDC 71699-0104-56)

XCOPRI Maintenance Pack

- **Directions for Use:** Take one 150 mg tablet and one 100 mg tablet by mouth once daily
- **Quantity:** 56 • **Refills:** (per HCP discretion)

350 mg
(200 mg and 150 mg)
(NDC 71699-0103-56)

XCOPRI Maintenance Pack

- **Directions for Use:** Take one 200 mg tablet and one 150 mg tablet by mouth once daily
- **Quantity:** 56 • **Refills:** (per HCP discretion)

Effective dose range 100 mg-400 mg

XCOPRI may be taken any time, whole or crushed, with or without food.

Patients with mild or moderate hepatic impairment: 200 mg/day is the maximum dosage. XCOPRI is not recommended for use in patients with severe hepatic impairment.

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV

CONTRAINDICATIONS

XCOPRI is contraindicated in any patients with known hypersensitivity to the compound or any of the components of the drug product.
XCOPRI is contraindicated in patients with Familial Short QT syndrome.

Please see additional Important Safety Information on the reverse side and full Prescribing Information.

IMPORTANT SAFETY INFORMATION and INDICATION for XCOPRI® (cenobamate tablets) CV (cont'd)

WARNINGS AND PRECAUTIONS

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including XCOPRI. DRESS has been reported, including one fatality, when XCOPRI is titrated rapidly (weekly or faster titration). No cases of DRESS were reported in an open-label safety study of 1339 partial-onset seizure patients when XCOPRI was initiated at 12.5 mg/day and titrated every two weeks. This finding does not establish that the risk of DRESS is prevented by a slower titration; however, XCOPRI should be initiated at 12.5 mg once daily and titrated every two weeks. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement. Eosinophilia is often present. If such signs or symptoms are present, the patient should be evaluated immediately. XCOPRI should be discontinued immediately and not restarted if an alternative etiology for the signs or symptoms cannot be established.

QT Shortening: XCOPRI can cause shortening of the QT interval. Caution should be used when administering XCOPRI and other drugs that shorten the QT interval as there may be a synergistic effect on the QT interval that would increase the QT shortening risk.

Suicidal Behavior and Ideation: Antiepileptic drugs (AEDs), including XCOPRI, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Advise patients, their caregivers, and/or families to be alert for these behavioral changes and report them immediately to a healthcare provider.

Neurological Adverse Reactions: XCOPRI causes dose-dependent increases in the neurologic adverse reactions including, dizziness, diplopia, disturbance in gait and coordination, somnolence, and fatigue.

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of XCOPRI is known.

Withdrawal of AEDs: As with all antiepileptic drugs, XCOPRI should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus. But if withdrawal is needed because of a serious adverse event, rapid discontinuation can be considered.

MOST COMMON ADVERSE REACTIONS

In adult adjunctive therapy placebo-controlled clinical studies, the most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, headache.

DOSING CONSIDERATIONS

Dosage adjustment of XCOPRI or other concomitant medications may be necessary.

- Consider gradually reducing phenytoin dosages by up to 50% during initial titration.
- Consider reducing dosages of phenobarbital and clobazam as needed when used concomitantly with XCOPRI. When XCOPRI and carbamazepine or lamotrigine are taken concomitantly, consider increasing dosages as needed of carbamazepine or lamotrigine.
- Consider increasing dosages as needed of drugs which are CYP2B6 and CYP3A substrates and decreasing dosages as needed of drugs which are CYP2C19 substrates.
- Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control.

Dosage reduction of XCOPRI may be considered in patients with mild to moderate and severe renal impairment. XCOPRI use is not recommended in end-stage renal disease.

The maximum recommended daily dose is 200 mg for patients with mild or moderate hepatic impairment. XCOPRI use is not recommended in patients with severe hepatic impairment.

DRUG ABUSE

XCOPRI is a Schedule V controlled substance.

INDICATION

XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.

For any medical questions or to report an adverse event, please contact Medical Information at 1-866-657-5574.

Reference: 1. XCOPRI [package insert]. Paramus, NJ: SK Life Science, Inc.

SK life science
a subsidiary of SK biopharmaceuticals

PM-US-XCOP-1339

Manufactured by: SK Life Science, Inc.
461 From Road, 5th Floor
Paramus, NJ 07652